Qualitative analysis of PD-L1 expression in non-small-cell lung cancer based on chest CT radiomics

[1]  Robert W. Hsieh,et al.  Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. , 2022, The Lancet. Oncology.

[2]  F. Ieva,et al.  PET/CT-based radiomics of mass-forming intrahepatic cholangiocarcinoma improves prediction of pathology data and survival , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Yong Xia,et al.  Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation , 2022, Journal of Hematology & Oncology.

[4]  S. Fanti,et al.  New Biomarkers With Prognostic Impact Based on Multitracer PET/CT Imaging in Neuroendocrine Neoplasms: The Light Leading Out of the Darkness in Challenging Tumors. , 2022, Clinical nuclear medicine.

[5]  G. Davidzon,et al.  Low-count whole-body PET with deep learning in a multicenter and externally validated study , 2021, npj Digital Medicine.

[6]  R. Boellaard,et al.  PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer , 2021, The Journal of Nuclear Medicine.

[7]  M. Pomper,et al.  First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients , 2021, The Journal of Nuclear Medicine.

[8]  I. Castiglioni,et al.  Radiomics and gene expression profile to characterise the disease and predict outcome in patients with lung cancer , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[10]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[11]  Wei-min Li,et al.  Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images , 2021, Theranostics.

[12]  Jianyong Wang,et al.  MSCS-DeepLN: Evaluating lung nodule malignancy using multi-scale cost-sensitive neural networks , 2020, Medical Image Anal..

[13]  M. Yadav,et al.  Probiotics in microbiome ecological balance providing a therapeutic window against cancer. , 2020, Seminars in cancer biology.

[14]  F. Giganti,et al.  Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multi-center study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Jianpeng Zhang,et al.  Semi-supervised adversarial model for benign-malignant lung nodule classification on chest CT , 2019, Medical Image Anal..

[16]  John O. Prior,et al.  18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  M. Ahn,et al.  Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. , 2019, Journal of Clinical Oncology.

[18]  M. Ahn,et al.  Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Weidong Cai,et al.  Knowledge-based Collaborative Deep Learning for Benign-Malignant Lung Nodule Classification on Chest CT , 2019, IEEE Transactions on Medical Imaging.

[20]  Yoganand Balagurunathan,et al.  Radiomic biomarkers from PET/CT multi-modality fusion images for the prediction of immunotherapy response in advanced non-small cell lung cancer patients , 2018, Medical Imaging.

[21]  S. Gettinger,et al.  Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  D. Rimm,et al.  Quantitative and Pathologist-Read comparison of the Heterogeneity of Programmed Death-Ligand 1(PD-L1) expression in Non-Small Cell Lung Cancer , 2016, Modern Pathology.

[23]  H. Aerts.  The Potential of Radiomic-Based Phenotyping in Precision Medicine: A Review. , 2016, JAMA oncology.

[24]  M. Vetizou,et al.  Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. , 2016, Immunity.

[25]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[26]  Marta Mańczuk,et al.  Lung cancer epidemiology: contemporary and future challenges worldwide. , 2016, Annals of translational medicine.

[27]  C. Marquette,et al.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[29]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[30]  G. Scagliotti,et al.  Addressing the unmet need in lung cancer: The potential of immuno-oncology. , 2015, Cancer treatment reviews.

[31]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[32]  Aurélien Marabelle,et al.  Immune Checkpoint Modulation for Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[33]  C. Graham,et al.  A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. , 2014, Cancer research.

[34]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[35]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[36]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.